LEO Pharma and the Parker Institute Partner to Advance Skin Disease Research
14.4.2025 10:00:00 CEST | LEO Pharma | Pressemeddelelse
- LEO Pharma and the Parker Institute have entered a 3-year partnership with the objective to advance dermatology research.
- The collaboration will leverage the Parker Institute’s expertise in trial design, artificial intelligence, and SingleCell RNA sequencing and LEO Pharma’s global leadership in serving 90 million patients annually in medical dermatology to enhance understanding and treatment of skin diseases.
- This initiative reinforces LEO Pharma's commitment to unlock external innovation and drive standard of care improvement.
Ballerup, Denmark, 14 April 2025 – LEO Pharma and the Parker Institute at Copenhagen University Hospital have formed an academic partnership to advance research and innovation in medical dermatology. This collaboration aims to produce high-quality research that enhances disease understanding and benefits patients. Furthermore, it aims to discover molecules that could potentially be integrated into broader pharmaceutical research and development efforts.
“We are proud to partner with the Parker Institute in LEO Pharma’s first academic collaboration of this kind, strengthening ties to the academic world to foster innovative research”, said Dr. Jacob Pontoppidan Thyssen, Chief Scientific Officer & Executive Vice President at LEO Pharma. “While breakthroughs in skin science have improved treatment options, over 1000 skin diseases still lack effective treatments. This partnership is an important step in addressing these unmet needs. By combining our expertise, we aim to positively impact patients worldwide."
The Parker Institute excels in trial design and clinical testing across all phases, from early to late stages, and their expertise spans all forms of analysis. LEO Pharma aims to leverage the Parker Institute’s translational expertise to better understand immunophenotyping and how these insights apply to skin diseases. The Parker Institute’s proficiency in target evaluation and disease understanding will add significantly to LEO Pharma's research efforts.
Additionally, the Parker Institute's expertise in artificial intelligence (AI) and SingleCell RNA sequencing helps to understand how individual cells behave within the immune system. This advanced method, using AI, allows for a more detailed examination of single-cell data, giving a clearer understanding of how skin diseases work.
Dr. Lars Erik Kristensen, Vice President, Head of External Innovation at LEO Pharma, said, "Having spent several years at the Parker Institute prior to joining LEO Pharma, I have witnessed the dedication and expertise in their research efforts. By partnering with the Parker Institute, we see potential for unlocking new insights and strengthen our ability to advance the standard of care within medical dermatology. Earlier this year, LEO Pharma announced a collaboration with DEBRA Research, and this new partnership with the Parker Institute further reinforces our commitment to also leverage external innovation and use the world as our lab. By joining forces with such a recognized partner, we aim to advance our understanding of skin diseases, improve patient care, and potentially discover molecules that may be involved in wider pharmaceutical research and development initiatives later on."
Henning Bliddal, Head of the Parker Institute, added, "We are thrilled to collaborate with LEO Pharma, a global leader in medical dermatology. We have a shared commitment to advancing medical research and ultimately improving the lives of people suffering from skin diseases such as psoriasis and psoriatic arthritis, making LEO Pharma a strong partner for us.”
The partnership between LEO Pharma and the Parker Institute is a 3-year agreement.
Kontakter
For further information please contact:
Media: Jeppe Ilkjær, Head of Media Relations, LEO Pharma, mobile +45 3050 2014
Billeder
About Parker Institute
The Parker Institute is part of Copenhagen University Hospital at Bispebjerg and Frederiksberg. The Parker Institute strives, through research with focus on locomotory and related disorders, to improve the status of health in the population via prevention at all levels, increasing knowledge of disease mechanisms and diagnostics, and by creating evidence-based treatments. The activities include observations and register based research, analysis of literature, and diagnostic studies of patient-reported outcome measures, clinical tests, imaging with ultrasound and MRI, and biomechanical evaluation, as well as randomised clinical and population interventions. The Institute participates in creation of evidence-based prevention and medicine and in the development of new treatment strategies. The staff counts a broad range of health professionals and scientists, all dedicated to research into clinical advances for patients and disease prevention for the population. For more information, visit www.parker.dk.
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological Conditions20.3.2026 14:30:00 CET | Pressemeddelelse
U.S. RELEASE MADISON, N.J. – March 20, 2026 – LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, Colorado), highlighting new real-world and clinical data across its medical dermatology portfolio and pipeline for inflammatory skin diseases. Key data to be presented by LEO Pharma at AAD 2026 include: ADBRY® (tralokinumab) 12‑month real‑world data from the TRACE study evaluating the safety and effectiveness of ADBRY among patients with atopic dermatitis (AD), including analyses in patients with hand and foot involvement and patients with skin of color.1-3 ANZUPGO® (delgocitinib) data evaluating outcomes with ANZUPGO cream 20 mg/g in adults with moderate-to-severe chronic hand eczema (CHE), including results across patients with and without prior systemic therapy exposure, further characterizing treatment response in this difficult-to-treat popul
LEO Pharma to nominate Kasper Fangel as new board member and Audit Committee Chair23.2.2026 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, February 23, 2026 – LEO Pharma today announced that Kasper Fangel, CEO of ISS A/S, will be nominated for election as a member of the Board of Directors at the Annual General Meeting (AGM) on 25 February 2026 and subsequently appointed as Chair of the Audit Committee. A Danish national, Kasper Fangel has built a distinguished career in corporate leadership and finance. At ISS A/S, one of the world’s largest workplace experience and facility management companies, he has played a pivotal role in shaping strategy and delivering sustainable performance on a global scale - serving in various leadership roles, including CFO from 2020 and CEO since 2023. His extensive expertise in governance, financial oversight, capital allocation, and strategic execution will be a valuable asset to LEO Pharma’s Board as the company advances its journey of sustainable growth and innovation in medical dermatology. "We are delighted to welcome Kasper to the Board and as our new Chair of the A
LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA margin18.2.2026 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 18 February, 2026 – In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and achieved a significant improvement in profitability, returning to positive net profit and free cash flow. The portfolio was strengthened by the launch of Anzupgo® in 10 additional markets, including the U.S., as well as the addition of Spevigo®. The pipeline was advanced through new late‑stage programs and strategic partnerships aimed at accelerating innovation. For 2026, revenue growth is expected to be 8-11% (CER), supporting further improvement in the adjusted EBITDA margin to 16-19%, alongside increased investments in innovation and LEO Pharma’s global platform. Financial highlights LEO Pharma’s revenue increased by 10% at constant exchange rates (CER) and by 8% in DKK to 13,499 million. Revenue growth was led by North America (+35% at CER), with Rest of World (+9% at CER) and Europe (+3% at CER) also contributing to t
LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS)21.1.2026 09:00:00 CET | Pressemeddelelse
The phase 3 trial DELTA CARE 1 will recruit up to 652 adult patients with lichen sclerosus (LS) to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle.1 The study initiation in LS is part of LEO Pharma's ambition to explore Anzupgo (delgocitinib) creme in additional indications beyond Chronic Hand Eczema (CHE), investigating the potential of delgocitinib as treatment option in skin diseases with high unmet medical need. There are currently no approved treatments specifically indicated for LS in the U.S. or in Europe. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,2,3 making it a potential treatment option for people living with LS disease.
LEO Pharma to present at the 44th annual J.P. Morgan Healthcare Conference7.1.2026 13:00:00 CET | Pressemeddelelse
Ballerup, Denmark, January 7, 2026 – LEO Pharma, a global leader in medical dermatology, announced today that CEO Christophe Bourdon will deliver a company update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 9:00 AM PST. With over 60 years of specialist expertise in medical dermatology and more than 90 million patients served in 70+ markets, LEO Pharma is uniquely positioned in one of healthcare’s most attractive and underserved sectors. Backed by an unmatched portfolio combining category‑leading brands with first‑in‑class innovations, the company is redefining standards of care for patients with high unmet needs. Entering 2026, LEO Pharma builds on the strong momentum of recent years, marked by robust top-line growth, significant margin expansion, and a promising pipeline. Leveraging its unique global platform, the LEO Pharma is advancing innovation as the preferred partner in medical dermatology. The J.P. Morgan Healthcare Con
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum